Ads
related to: pfizerinsights.pfizer.com has been visited by 10K+ users in the past month
Search results
Kansas accuses Pfizer of misleading public about COVID vaccine in lawsuit By Reuters
Investing.com· 3 days agoIn a lawsuit filed in the District Court of Thomas County, the state said the New York-based...
Is It Too Late to Buy Pfizer Stock?
Motley Fool via Yahoo Finance· 7 days agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 7 hours agoUsually, RSV causes coldlike symptoms in most people. But in newborns and older adults it can be...
Kansas attorney general sues Pfizer over marketing of COVID-19 vaccine
The Day· 3 days agoKansas Attorney General Kris Kobach is suing the pharmaceutical company Pfizer, alleging it...
Pfizer Inc. (NYSE:PFE) Shares Sold by CoreFirst Bank & Trust
ETF DAILY NEWS· 3 days agoCoreFirst Bank & Trust decreased its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with ...
The FDA Now Wants Fall COVID Vaccines to Target KP.2—But Not All Manufacturers Can Pivot
Verywell Health via Yahoo News· 55 minutes agoLess than a week after telling COVID-19 vaccine manufacturers to target the JN.1 variant this fall,...
Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
Zacks· 3 days agoFree Report) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. This has lagged the ...
Biden admin seeks to delay releasing data on COVID vaccine reactions, report says
NBC Montana· 12 hours agoThe Biden administration on Tuesday asked for a delay in releasing data on reactions to COVID-19...
Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)
ETF DAILY NEWS· 2 days agoPfizer (NYSE:PFE – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report issued on Monday, Benzinga reports ...
Pfizer 'can't rule out' layoffs in North Carolina after gene therapy flub - Triangle Business...
The Business Journals· 2 days agoLayoffs could by on the way at Pfizer's massive facility in Sanford after the company's gene therapy...